ReviewArchives of microbiology2025
Bacterial programmed cell death and toxin-antitoxin system in bacteria.
Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bacteriophage therapy for antimicrobial-resistant, biofilm‑associated diabetic foot infection: delivery routes, phage antibiotic synergy, and practical wound‑care integration.Archives of microbiology · 2026Review
- Microbial systems for azo dye biodegradation: enzymatic mechanisms, microbial consortia, and emerging biotechnological strategies.Microbial cell factories · 2026Review
- Role of hydrogen sulfide in bacterial antibiotic tolerance: from mechanisms to therapeutic targeting.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial programmed cell death (PCD) is a controlled and regulated mechanism of enormous significance in survival, stress adaptation, and biofilm persistence. Bacterial cells actively trigger their death based on internal or external stimuli. This death is not like accidental or passive death (being caused by antibiotics or through lysis, etc.). The toxin-antitoxin (TA) systems are key players in PCD, contributing significantly to antibiotic resistance and bacterial adaptation. The present descriptive review evaluates current literature dealing with the phenomenon of bacterial PCD with particular focus on the molecular biology of Type I and II TA systems (e.g., mazEF, hipBA, hok/sok). Their functions are involved in bacterial stress responses, biofilm growth, and persistence seen in Pseudomonas aeruginosa and Escherichia coli. The TA systems are a combination of toxins that disturb cellular processes (mRNA cleavage, membrane depolarization) and antitoxins that neutralize toxins to modulate PCD. The mazEF TA system blocks protein synthesis, whereas the hok/sok system results in cellular death thereby maintaining plasmid stability. PCD also encourages biofilm formation by eDNA, thereby enhancing antibiotic resistance and structural integrity, which enables bacteria to persist and make infections difficult to treat. Bioinformatic tools and experimental evidence from genetic knock-out and stress response testing studies were combined to clarify the functions of TA systems and regulation under environmental factors. Understanding these mechanisms allows the development of new antibacterial approaches by targeting TA systems to combat antibiotic resistance and reduce persistence. TA systems are redundant; multiple systems with similar mechanisms can synergistically increase persistence, as seen in the deletion of multiple TA loci in E. coli that resulted in reduced persister cell formation. Future studies should explore the interaction between TA systems with other stress-response patterns to develop target intervention mechanisms that can inhibit bacterial survivability without environmental effects.
Indexed as
Identifiers
40689981What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.